Cyril Amarchand Mangaldas has advised NYSE-listed chemistry firm The Chemours Company on its strategic partnership with Indian chemical manufacturer SRF, which was guided by AZB & Partners.
The Chemours and SRF deal is a strategic partnership focused on manufacturing advanced fluoropolymers and fluoroelastomers at SRF’s Dahej facility in India. The collaboration is set to start production within approximately 12 months, aiming to serve global markets across industries such as semiconductors, automotive, aerospace, chemical processing, and oil and gas.
This partnership enhances Chemours’ global supply chain, providing operational flexibility and access to capacity without upfront capital investment from Chemours. SRF will leverage its manufacturing capabilities alongside Chemours’ advanced technology and quality standards, positioning SRF as a trusted manufacturer of advanced materials with expected revenue growth from fiscal 2027.
“This arrangement with SRF exemplifies our Pathway to Thrive strategy as we continue to shift our product mix to higher value applications, enhancing our position as a trusted supplier paired with our commitment to responsible manufacturing practices,” said Denise Dignam, Chemours President and CEO.
The CAM team was led by partner Soumya Srivastava, with support from associate Samaksh Khanna. Partner Kaustav Kundu assisted in competition aspects of the transaction.
AZB’s deal team comprised senior partner Daksh Trivedi, senior associate Sourya Donkada, and associate Aakaanksha Akella.
